TG Therapeutics Inc (NASDAQ: TGTX) is 3.85% higher on its value in year-to-date trading and has touched a low of $12.84 and a high of $36.84 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TGTX stock was last observed hovering at around $29.04 in the last trading session, with the day’s gains setting it 2.22%.
Currently trading at $31.26, the stock is 4.19% and -1.05% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.42 million and changing 7.64% at the moment leaves the stock 36.14% off its SMA200. TGTX registered 97.72% gain for a year compared to 6-month gain of 59.65%. The firm has a 50-day simple moving average (SMA 50) of $31.5927 and a 200-day simple moving average (SMA200) of $22.962225.
The stock witnessed a -2.92% loss in the last 1 month and extending the period to 3 months gives it a 28.91%, and is 7.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.66% over the week and 5.08% over the month.
TG Therapeutics Inc (TGTX) has around 264 employees, a market worth around $4.87B and $264.79M in sales. Fwd P/E is 30.80. Profit margin for the company is -5.42%. Distance from 52-week low is 143.46% and -15.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.23%).
with sales reaching $99.36M over the same period.The EPS is expected to grow by 22.22% this year, but quarterly earnings will post 37.05% year-over-year. Quarterly sales are estimated to grow 125.97% in year-over-year returns.
TG Therapeutics Inc (TGTX) Top Institutional Holders
395.0 institutions hold shares in TG Therapeutics Inc (TGTX), with institutional investors hold 73.19% of the company’s shares. The shares outstanding are 155.78M, and float is at 140.52M with Short Float at 18.50%. Institutions hold 66.23% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.69 million shares valued at $243.58 million. The investor’s holdings represent 9.3645% of the TGTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 11.39 million shares valued at $202.6 million to account for 7.7891 of the shares outstanding. The other top investors are STATE STREET CORP which holds 6.7 million shares representing 4.5798% and valued at over $119.12 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 2.4934 of the shares totaling 3.65 million with a market value of $64.85 million.
TG Therapeutics Inc (TGTX) Insider Activity
The most recent transaction is an insider sale by Power Sean A, the company’s CFO. SEC filings show that Power Sean A sold 11,337 shares of the company’s common stock on Jan 03 ’25 at a price of $30.29 per share for a total of $0.34 million. Following the sale, the insider now owns 0.67 million shares.
TG Therapeutics Inc disclosed in a document filed with the SEC on Jan 06 ’25 that Power Sean A (CFO) sold a total of 10,021 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $28.53 per share for $0.29 million. Following the transaction, the insider now directly holds 0.66 million shares of the TGTX stock.
Still, SEC filings show that on Jan 06 ’25, Power Sean A (Officer) Proposed Sale 10,021 shares at an average price of $28.53 for $0.29 million. The insider now directly holds shares of TG Therapeutics Inc (TGTX).
